HEPTA Medical develops a device that integrates a minimally invasive thermal ablation probe introduced via natural orifices to destroy early lung tumors by heat. The company highlights a large unmet need given more than 2.2 million new lung cancer cases and roughly 1.8 million deaths annually worldwide. Founded in 2019 and based in Suresnes, HEPTA employs around a dozen people. Financially, it has just closed a €10 million Series A to fund growth and hiring. The startup plans to initiate its first clinical trials in the second quarter of 2026. Its investor base includes UI Investissement and Supernova Invest as new participants alongside Bpifrance, M & L, Sofinnova Partners, Cléry and MD Start.

Total raised

$18M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2026